Which carbapenemase-targeting option is combined with a beta-lactam to combat ESBL or KPC-producing organisms?

Prepare for the Antibacterials (ABX) Exam. Study with flashcards and multiple-choice questions, each question comes with hints and explanations. Get ready to ace your test!

Multiple Choice

Which carbapenemase-targeting option is combined with a beta-lactam to combat ESBL or KPC-producing organisms?

Explanation:
The test is about overcoming beta-lactamase–mediated resistance by pairing a carbapenem with a beta-lactamase inhibitor. Meropenem-vaborbactam combines meropenem with vaborbactam, a potent inhibitor that blocks many serine beta-lactamases, including KPC. This pairing restores activity against ESBL- and KPC-producing organisms, making it the best choice when those resistances are present. Imipenem-cilastatin uses cilastatin to prevent renal degradation but does not inhibit beta-lactamases, so it won’t counter carbapenemase-mediated resistance. Doripenem and ertapenem are carbapenems without an accompanying beta-lactamase inhibitor, so their effectiveness against ESBL- or KPC-producing bacteria is more limited.

The test is about overcoming beta-lactamase–mediated resistance by pairing a carbapenem with a beta-lactamase inhibitor. Meropenem-vaborbactam combines meropenem with vaborbactam, a potent inhibitor that blocks many serine beta-lactamases, including KPC. This pairing restores activity against ESBL- and KPC-producing organisms, making it the best choice when those resistances are present. Imipenem-cilastatin uses cilastatin to prevent renal degradation but does not inhibit beta-lactamases, so it won’t counter carbapenemase-mediated resistance. Doripenem and ertapenem are carbapenems without an accompanying beta-lactamase inhibitor, so their effectiveness against ESBL- or KPC-producing bacteria is more limited.

More practice questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy